

Ideal Cures wins patent revocation case against Colorcon Inc. USA

Tuesday, August 31, 2010 14:45 IST

Our Bureau, Mumbai

Mumbai based Ideal Cures has won a landmark victory in a patent revocation case against Colorcon Inc. USA. The company had filed a revocation under section 117 D (1) of the Patents Act 1970 against the grant of Patent no. 191636 to Colorcon Inc for aqueous moisture barrier product under the brand name 'Opadry AMB'. The Patent was revoked by the Intellectual Property Appellate Board (IPAB) by its Order no. 90, 2010 and thereafter the IPAB directed the controller of patent to remove the patent no. 191636 from the register of patent.

"It is a first major victory for an Indian pharmaceutical excipient manufacturing company with respect to revocation of patent. Last year we had successfully won a pre-grant opposition against BPSI Holding parent company of Colorcon Asia for grant of a similar patent of film coating material manufactured and marketed by them," informed Suresh Pareek, managing director, Ideal Cures.

Film coating materials which are produced by Ideal Cures play a very important role in the pharmaceutical preparation of solid oral dosage forms like tablets. The excipients play a vital role in the improvement of the shelf life of the medicine, provide physical and chemical protection to drugs, provides sustain release control and time release of drug, to protect drug from gastric environment in the stomach with an acid resistant enteric coating, release pattern i.e. release of drug in the body as well as to mask taste & odour and colour of the active ingredient. Ideal Cures produces the coating material under the brand name of INSTACOAT.

According to Pareek, it is an important milestone for the Indian pharmaceutical industry as a whole as revocation of this patent will give cost effective solutions to the industry by having an alternative choice.

Ideal Cures has its own R&D facility recognised by the Department of Scientific & Industrial Research (DSIR) and has their own eight patents granted for various technologies in film coating. The company is actively engaged in R&D in the field of excipients. The company is setting up second R&D centre for doing research on the products for New Drug Delivery Systems (NDDS) and MUPS (Multiple Unit pellet system). The company also has plans to enter in research and development of Nano Particle system for NDDS and MUPS.